This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medifast (MED) Tumbles 25% in 3 Months: Should You Buy Now?
by Zacks Equity Research
Medifast (MED) is encountering difficulties in attracting customers due to a reduction in the number of active OPTAVIA Coaches and diminished productivity per Coach.
Medifast (MED) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Medifast's (MED) Q2 results highlight the challenges of poor customer acquisition. However, the company is focusing strategically on medically supported weight loss, indicating potential for growth.
Medifast (MED) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of 155.56% and 5.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Medifast (MED) Q2 Earnings in the Cards: Factors to Watch
by Zacks Equity Research
Medifast's (MED) Q2 results are likely to reflect customer acquisition challenges stemming from the growth of GLP-1 medications in markets.
Post Holdings (POST) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Post Holdings (POST) delivered earnings and revenue surprises of 27.27% and 3.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Medifast (MED) Lags Industry in 3 Months: How to Play Ahead?
by Zacks Equity Research
While Medifast (MED) is implementing a series of measures to propel its growth trajectory, the challenges related to customer acquisition and high marketing expenses keep it in a tight spot.
Medifast (MED) Tumbles More Than 40% in 3 Months: Here's Why
by Zacks Equity Research
Medifast (MED) battles persistent customer acquisition challenges aggravated by macroeconomic factors and the rising popularity of weight loss medications.
Medifast (MED) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Medifast's (MED) first-quarter results reflect challenges related to a decline in active earning OPTAVIA Coaches, lower coach productivity and soft sales volume.
Medifast's (MED) Transformation on Track Amid Macro Headwinds
by Zacks Equity Research
Medifast (MED) adapts to shifting consumer behavior to maintain its relevance. However, it is facing difficulties in attracting customers due to the rapidly changing economy and inflation.
MEDIFAST (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
MEDIFAST (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medifast (MED) Soars 5.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Medifast (MED) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Innovations Aid Medifast (MED), Lower Customer Attraction Ails
by Zacks Equity Research
Medifast (MED) is foraying into medically supported weight management and sports nutrition segments. However, it continues to encounter difficulties in attracting customers.
Medifast (MED) Q4 Earnings Beat Estimates, Revenues Dip Y/Y
by Zacks Equity Research
Medifast's (MED) Q4 results reflect the impacts of poor customer acquisition. However, it is showing resilience, banking on its strategic focus on medically supported weight loss, indicating potential for growth.
Medifast (MED) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of 10.10% and 9.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Medifast (MED) Q4 Earnings Coming Up: What Should You Know?
by Zacks Equity Research
Medifast's (MED) fourth-quarter results are likely to reflect the impacts of macroeconomic challenges like inflation, while key growth initiatives like innovation bode well.
Mondelez (MDLZ) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Mondelez (MDLZ) delivered earnings and revenue surprises of 7.69% and 0.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Medifast's (MED) Holistic Health Solution, Innovation Bode Well
by Zacks Equity Research
Medifast's (MED) focus on combining lifestyle coaching with innovative health solutions and targeting diverse markets bode well amid challenges in customer acquisition and high costs.
Medifast (MED) Collaborates With LifeMD, Discontinues Dividend
by Zacks Equity Research
Medifast (MED) penetrates the medically supported weight loss market via a collaboration with LifeMD, Inc. (LFMD). The company discontinues quarterly cash dividends.
Here's How Much You'd Have If You Invested $1000 in Medifast a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Why Is Medifast (MED) Down 1.1% Since Last Earnings Report?
by Zacks Equity Research
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medifast (MED) Poised on OPTAVIA ACTIVE Line Amid Cost Woes
by Zacks Equity Research
Medifast (MED) is proactively positioning itself to tap into the increasing demand for weight loss medications, showcasing a commitment to staying in touch with market trends.
Medifast (MED) Q3 Earnings Top Estimates, Revenues Decline Y/Y
by Zacks Equity Research
Medifast's (MED) Q3 results reflect challenges in customer acquisition. However, cost-reduction efforts and efficiency improvements as part of the "Fuel for the Future" plan bode well.
Medifast (MED) Queues for Q3 Earnings: What Awaits the Stock?
by Zacks Equity Research
Medifast's (MED) third-quarter results are likely to reflect concerns surrounding customer acquisition amid a challenging landscape. However, a focus on growth plans bodes well.
Sysco (SYY) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Sysco (SYY) delivered earnings and revenue surprises of 4.90% and 0.38%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Medifast (MED) Poised on Expansion Initiatives Amid Cost Woes
by Zacks Equity Research
Medifast (MED) is making significant strides in its digital transformation efforts and expanding its OPTAVIA lifestyle solution to meet the increasing demand in the health and wellness market.